Compare KRKR & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRKR | TCRT |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 8.1M |
| IPO Year | 2019 | N/A |
| Metric | KRKR | TCRT |
|---|---|---|
| Price | $4.08 | $3.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.8K | ★ 63.8K |
| Earning Date | 09-26-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,966,526.00 | $6,000.00 |
| Revenue This Year | $182.55 | $5,680,500.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.90 | $1.31 |
| 52 Week High | $21.36 | $6.20 |
| Indicator | KRKR | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 36.37 | 59.25 |
| Support Level | $4.13 | $3.92 |
| Resistance Level | $4.65 | $4.50 |
| Average True Range (ATR) | 0.32 | 0.37 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 19.17 | 70.73 |
36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.